real-world outcomes of patients with bv and anti-pd-1 intolerant chl: the impact of allosct & car-t
Published 5 months ago • 33 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
4:59
real-world long-term outcomes of patients with lbcl treated with axi-cel
-
2:33
real-world study evaluating the outcomes of patients with r/r all receiving hsct
-
4:21
mrd as a monitoring technique of allosct and car-t in aml/all
-
1:38
challenges of car-t therapy in the real-world setting
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
0:44
the role of allosct for r/r lbcl in the era of car-t therapy
-
55:08
real-world car-t data update
-
9:25
mgus diagnosis: a step-by-step approach
-
5:00
diagnosing and treating al amyloidosis: a 2020 update from dr morie gertz
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:45
car-t treatment outcomes: mm real-world data
-
2:05
the cost-effectiveness of car t-cell therapy
-
1:02
the use of car-t cell products in a real-world setting
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml
-
5:09
the evolving role of nurses in the field of car-t
-
1:15
allosct outcomes in patients who achieve cr with car-t versus chemotherapy in t-all/lbl
-
1:38
the future of car-t for hematological malignancies and solid tumors
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
0:56
real-world survival in patients with mixed phenotype attr-cm treated with tafamidis
-
2:43
healthcare utilization & end of life outcomes in patients receiving car-t